Pharmacokinetic and Pharmacodynamic Evaluation for Tissue-selective Inhibition of Cholesterol Synthesis by Pravastatin

Overview

Journal J Pharmacokinet Biopharm

Specialty Pharmacology

Date 1999 Mar 31

PMID 10098103

Citations 4

Authors

T Hatanaka

S Honda

S Sasaki

K Katayama

T Koizumi

Affiliations

Soon will be listed here.

Abstract

The tissue-selective inhibition of cholesterol synthesis by pravastatin was evaluated pharmacokinetically and pharmacodynamically. Plasma, tissue, urine, and bile concentrations were measured after i.v. bolus injection of pravastatin to rats at various doses. The total body clearance and steady state volume of distribution decreased with increasing dose. A saturable biliary excretion was also observed. The time course of plasma and liver concentrations was described by a three-compartment model, consisting of a central compartment, a deep compartment with an nonsaturable uptake process, and a shallow compartment with saturable uptake and nonsaturable elimination processes. It suggests that a mechanism for the decrease in the total body clearance and distribution volume might be explained by a saturation of pravastatin uptake into the liver. Plasma concentration data after oral administration was also fitted to the same model by connecting an absorption compartment to the shallow compartment. The inhibitory activity of pravastatin against cholesterol synthesis in liver could be related to the concentration in the shallow compartment via a sigmoidal Emax model and the obtained pharmacodynamic parameters were comparable to those in vitro. Results suggest that the carrier-mediated hepatic uptake of pravastatin is actually responsible for the hepatoselective inhibition of cholesterol synthesis under physiological conditions.

Citing Articles

The Effect of Inflammatory Bowel Disease and Irritable Bowel Syndrome on Pravastatin Oral Bioavailability: In vivo and in silico evaluation using bottom-up wbPBPK modeling.

Alsmadi M, Abudaqqa A, Idkaidek N, Qinna N, Al-Ghazawi A AAPS PharmSciTech. 2024; 25(4):86.

PMID: 38605192 DOI: 10.1208/s12249-024-02803-z.

Pravastatin and Gemfibrozil Modulate Differently Hepatic and Colonic Mitochondrial Respiration in Tissue Homogenates from Healthy Rats.

Herminghaus A, Laser E, Schulz J, Truse R, Vollmer C, Bauer I Cells. 2019; 8(9).

PMID: 31461874 PMC: 6769625. DOI: 10.3390/cells8090983.

SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients.

Zhang W, Chen B, Ozdemir V, He Y, Zhou G, Peng D Br J Clin Pharmacol. 2007; 64(3):346-52.

PMID: 17439540 PMC: 2000640. DOI: 10.1111/j.1365-2125.2007.02892.x.

Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events.

Hatanaka T Clin Pharmacokinet. 2001; 39(6):397-412.

PMID: 11192473 DOI: 10.2165/00003088-200039060-00002.

References

Illingworth D, Tobert J . A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther. 1994; 16(3):366-85; discussion 365. View

Yamazaki M, Suzuki H, Hanano M, Tokui T, Komai T, Sugiyama Y . Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol. 1993; 264(1 Pt 1):G36-44. DOI: 10.1152/ajpgi.1993.264.1.G36. View

Singhvi S, Pan H, Morrison R, Willard D . Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol. 1990; 29(2):239-43. PMC: 1380090. DOI: 10.1111/j.1365-2125.1990.tb03626.x. View

Ziegler K, Hummelsiep S . Hepatoselective carrier-mediated sodium-independent uptake of pravastatin and pravastatin-lactone. Biochim Biophys Acta. 1993; 1153(1):23-33. DOI: 10.1016/0005-2736(93)90272-2. View

Endo A, Kuroda M, Tsujita Y . ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo). 1976; 29(12):1346-8. DOI: 10.7164/antibiotics.29.1346. View

Koga T, Shimada Y, Kuroda M, Tsujita Y, Hasegawa K, Yamazaki M . Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim Biophys Acta. 1990; 1045(2):115-20. DOI: 10.1016/0005-2760(90)90139-o. View

Komai T, Kawai K, Tokui T, Tokui Y, Kuroiwa C, Shigehara E . Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys. Eur J Drug Metab Pharmacokinet. 1992; 17(2):103-13. DOI: 10.1007/BF03188778. View

Bocan T, Ferguson E, McNally W, Uhlendorf P, Bak Mueller S, Dehart P . Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors. Biochim Biophys Acta. 1992; 1123(2):133-44. DOI: 10.1016/0005-2760(92)90103-3. View

Levy G . Targeted drug delivery--some pharmacokinetic considerations. Pharm Res. 1987; 4(1):3-4. DOI: 10.1023/a:1016413523833. View

10.

Everett D, Chando T, DiDonato G, Singhvi S, Pan H, Weinstein S . Biotransformation of pravastatin sodium in humans. Drug Metab Dispos. 1991; 19(4):740-8. View

11.

Tsuji A, Takanaga H, Tamai I, Terasaki T . Transcellular transport of benzoic acid across Caco-2 cells by a pH-dependent and carrier-mediated transport mechanism. Pharm Res. 1994; 11(1):30-7. DOI: 10.1023/a:1018933324914. View

12.

Berman M, SHAHN E, Weiss M . The routine fitting of kinetic data to models: a mathematical formalism for digital computers. Biophys J. 1962; 2:275-87. PMC: 1366372. DOI: 10.1016/s0006-3495(62)86855-6. View

13.

Lin J, Sugiyama Y, AWAZU S, Hanano M . Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J Pharmacokinet Biopharm. 1982; 10(6):649-61. DOI: 10.1007/BF01062546. View

14.

van Vliet A, van Thiel G, Huisman R, Moshage H, Yap S, Cohen L . Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types. Biochim Biophys Acta. 1995; 1254(1):105-11. DOI: 10.1016/0005-2760(94)00176-y. View

15.

Koga T, Fukuda K, Shimada Y, Fukami M, Koike H, Tsujita Y . Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. The relationship between inhibition of de novo sterol synthesis and active drug concentrations in the liver, spleen and testis in rat. Eur J Biochem. 1992; 209(1):315-9. DOI: 10.1111/j.1432-1033.1992.tb17291.x. View

16.

Komai T, Shigehara E, Tokui T, Koga T, Ishigami M, Kuroiwa C . Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. Biochem Pharmacol. 1992; 43(4):667-70. DOI: 10.1016/0006-2952(92)90228-b. View

17.

Keller G, Barton M, Shapiro D, Singer S . 3-Hydroxy-3-methylglutaryl-coenzyme A reductase is present in peroxisomes in normal rat liver cells. Proc Natl Acad Sci U S A. 1985; 82(3):770-4. PMC: 397128. DOI: 10.1073/pnas.82.3.770. View

18.

Hoeg J, BREWER Jr H . 3-Hydroxy-3-methylglutaryl--coenzyme A reductase inhibitors in the treatment of hypercholesterolemia. JAMA. 1987; 258(24):3532-6. View

19.

Tsujita Y, Kuroda M, Shimada Y, Tanzawa K, Arai M, Kaneko I . CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim Biophys Acta. 1986; 877(1):50-60. DOI: 10.1016/0005-2760(86)90117-7. View

20.

Germershausen J, HUNT V, Bostedor R, Bailey P, KARKAS J, ALBERTS A . Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem Biophys Res Commun. 1989; 158(3):667-75. DOI: 10.1016/0006-291x(89)92773-3. View